Print
|
Close
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Active:
No
Cancer Type:
Solid Tumor
Unknown Primary
NCT ID:
NCT03510104
Trial Phases:
Phase I
Protocol IDs:
2843-1001 (primary)
NCI-2018-01102
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Meryx, Inc.
NCI Full Details:
http://clinicaltrials.gov/show/NCT03510104
Summary
This first-in-human open-label, dose escalation study is designed to evaluate the safety,
tolerability, and PK of MRX-2843 in subjects with relapsed/refractory advanced and/or
metastatic solid tumors.
Treatment Sites in Georgia
Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.